相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors
Cristina Valero et al.
NATURE COMMUNICATIONS (2021)
High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
D. J. McGrail et al.
ANNALS OF ONCOLOGY (2021)
The Spectrum of Benefit from Checkpoint Blockade in Hypermutated Tumors
Benoit Rousseau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer
G. L. Banna et al.
ESMO OPEN (2021)
Neutrophil-to-lymphocyte ratio and lactate dehydrogenase as biomarkers for urothelial cancer treated with immunotherapy
G. L. Banna et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2020)
Burden of tumor mutations, neoepitopes, and other variants are weak predictors of cancer immunotherapy response and overall survival
Mary A. Wood et al.
GENOME MEDICINE (2020)
Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient
Giovanni Rossi et al.
CANCERS (2020)
The FDA approval of pembrolizumab for patients with TMB >10 mut/Mb: was it a wise decision? No
V. Prasad et al.
ANNALS OF ONCOLOGY (2020)
The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) >= 10: a decision centered on empowering patients and their physicians
V. Subbiah et al.
ANNALS OF ONCOLOGY (2020)
Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment
Amblessed E. Onuma et al.
GENE EXPRESSION (2020)
KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden
D. Marinelli et al.
ANNALS OF ONCOLOGY (2020)
Promising predictors of checkpoint inhibitor response in NSCLC
Friedlaender Alex et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2020)
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
T. Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Comparison of TCGA and GENIE genomic datasets for the detection of clinically actionable alterations in breast cancer
Pushpinder Kaur et al.
SCIENTIFIC REPORTS (2019)
Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial
Martin Reck et al.
EUROPEAN JOURNAL OF CANCER (2019)
Tumor mutational burden quantification from targeted gene panels: major advancements and challenges
Laura Fancello et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy
Aaron M. Goodman et al.
CANCER IMMUNOLOGY RESEARCH (2019)
How liquid biopsies can change clinical practice in oncology
G. Siravegna et al.
ANNALS OF ONCOLOGY (2019)
Cancer Neoantigens
Ton N. Schumacher et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 37, 2019 (2019)
Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkers
Hao-Xiang Wu et al.
ANNALS OF TRANSLATIONAL MEDICINE (2019)
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert M. Samstein et al.
NATURE GENETICS (2019)
APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapy
Arnelie Boichard et al.
ONCOIMMUNOLOGY (2019)
Implementing TMB measurement in clinical practice: considerations on assay requirements
Reinhard Buettner et al.
ESMO OPEN (2019)
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
Ferdinandos Skoulidis et al.
NATURE REVIEWS CANCER (2019)
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer
Matthew D. Hellmann et al.
CANCER CELL (2018)
Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature
Katharina Schwarze et al.
GENETICS IN MEDICINE (2018)
Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations
Matteo Allegretti et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)
Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors
Aaron M. Goodman et al.
JAMA ONCOLOGY (2018)
Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer
Siddhartha Devarakonda et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
David R. Gandara et al.
NATURE MEDICINE (2018)
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy
Roberto Ferrara et al.
JAMA ONCOLOGY (2018)
Concordance between Comprehensive Cancer Genome Profiling in Plasma and Tumor Specimens
Judith N. Mueller et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Arjun V. Balar et al.
LANCET (2017)
Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis
Samra Turajlic et al.
LANCET ONCOLOGY (2017)
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Aaron M. Goodman et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia?
Michaela Kotrova et al.
MOLECULAR DIAGNOSIS & THERAPY (2017)
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Ahmet Zehir et al.
NATURE MEDICINE (2017)
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
J. Bellmunt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Zachary R. Chalmers et al.
GENOME MEDICINE (2017)
High expression of PD-1 ligands is associated with kataegis mutational signature and APOBEC3 alterations
Amelie Boichard et al.
ONCOIMMUNOLOGY (2017)
Comparison of tumor mutational burden (TMB) across tumor tissue and circulating tumor DNA (ctDNA)
Andrew A. Davis et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy
Yulian Khagi et al.
CLINICAL CANCER RESEARCH (2017)
CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of Their Inhibition
Elizabeth I. Buchbinder et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2016)
Mutational Landscape and Sensitivity to Immune Checkpoint Blockers
Roman M. Chabanon et al.
CLINICAL CANCER RESEARCH (2016)
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
Tanguy Y. Seiwert et al.
LANCET ONCOLOGY (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine
Andrea Garofalo et al.
GENOME MEDICINE (2016)
Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
Douglas B. Johnson et al.
CANCER IMMUNOLOGY RESEARCH (2016)
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
Sandip Pravin Patel et al.
MOLECULAR CANCER THERAPEUTICS (2015)
High-Throughput Sequencing Technologies
Jason A. Reuter et al.
MOLECULAR CELL (2015)
Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice
Luis Felipe Campesato et al.
ONCOTARGET (2015)
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Analysis, Optimization and Verification of Illumina-Generated 16S rRNA Gene Amplicon Surveys
Michael C. Nelson et al.
PLOS ONE (2014)
Integrated analysis of germline and somatic variants in ovarian cancer
Krishna L. Kanchi et al.
NATURE COMMUNICATIONS (2014)
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
Hirokazu Matsushita et al.
NATURE (2012)
Assuring the quality of next-generation sequencing in clinical laboratory practice
Amy S. Gargis et al.
NATURE BIOTECHNOLOGY (2012)
Double indexing overcomes inaccuracies in multiplex sequencing on the Illumina platform
Martin Kircher et al.
NUCLEIC ACIDS RESEARCH (2012)
Microsatellite Instability in Colorectal Cancer
C. Richard Boland et al.
GASTROENTEROLOGY (2010)
Genomic medicine - Hereditary colorectal cancer
HT Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
分享论文
